Skip to main content
. 2014 Jun 23;210(12):1938–1945. doi: 10.1093/infdis/jiu346

Table 3.

Incidence of Malaria and Parasite Prevalence During and After Pregnancy Among Pregnant Study Participants Who Were Randomly Assigned to Receive Efavirenz (EFV)–Based Antiretroviral Therapy (ART) or Lopinavir/Ritonavir (LPV/r)–Based ART

Treatment Arm During Pregnancy
After Pregnancy
Participants, No. Malaria Episodes, No. PYAR, No. Malaria Incidence, Episodes/PYAR IRR (95% CI) P Value Participants, No. Malaria Episodes, No. PYAR, No. Malaria Incidence, Episodes/PYAR IRR (95% CI) P Value
EFV-based ART 195 17 63.5 0.27 1.0 (reference) 187 13 159.9 0.08 1.0 (reference)
LPV/r-based ART 194 17 62.3 0.27 1.01 (.49–2.09) .97 190 21 164.9 0.13 1.55 (.66–3.63) .31
Asymptomatic Parasitemia, Prevalencea
Prevalence Ratio (95% CI)

Asymptomatic Parasitemia, Prevalencea
Prevalence Ratio (95% CI)
EFV-based ART 22/795 (2.8) 1.0 (reference) 43/1659 (2.6) 1.0 (reference)
LPV/r-based ART 13/786 (1.7) 0.59 (.28–1.24) .17 36/1753 (2.1) 0.78 (.38–1.62) .51

Abbreviations: CI, confidence interval; IRR, incidence rate ratio; PYAR, person-years at risk.

a Data are routine blood smears with positive results/routine blood smears evaluated (%).